Format

Send to

Choose Destination
J Natl Compr Canc Netw. 2018 Sep;16(9):1041-1053. doi: 10.6004/jnccn.2018.0072.

NCCN Guidelines Insights: Bladder Cancer, Version 5.2018.

Author information

1
University of Colorado Cancer Center
2
Moffitt Cancer Center
3
Huntsman Cancer Institute at the University of Utah
4
Patient Advocate
5
Mayo Clinic Cancer Center
6
Stanford Cancer Institute
7
University of Wisconsin Carbone Cancer Center
8
Massachusetts General Hospital Cancer Center
9
UCSF Helen Diller Family Comprehensive Cancer Center
10
Fox Chase Cancer Cente
11
Roswell Park Comprehensive Cancer Center
12
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
13
Memorial Sloan Kettering Cancer Center
14
Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute
15
Duke Cancer Institute
16
University of Michigan Rogel Cancer Center
17
UC San Diego Moores Cancer Center
18
Fred & Pamela Buffett Cancer Center
19
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
20
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
21
City of Hope Comprehensive Cancer Center
22
St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center
23
Yale Cancer Center/Smilow Cancer Hospital
24
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
25
University of Washington/Seattle Cancer Care Alliance
26
Dana-Farber/Brigham and Women’s Cancer Center
27
The University of Texas MD Anderson Cancer Center
28
Vanderbilt-Ingram Cancer Center
29
National Comprehensive Cancer Network

Abstract

The NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer. These NCCN Guidelines Insights discuss important updates to the 2018 version of the guidelines, including implications of the 8th edition of the AJCC Cancer Staging Manual on treatment of muscle-invasive bladder cancer and incorporating newly approved immune checkpoint inhibitor therapies into treatment options for patients with locally advanced or metastatic disease.

PMID:
30181416
DOI:
10.6004/jnccn.2018.0072

Supplemental Content

Full text links

Icon for Sheridan PubFactory
Loading ...
Support Center